111In-J591
- Generic Name
- 111In-J591
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2024-07-25
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
- Target Recruit Count
- 430
- Registration Number
- NCT06520345
- Locations
- 🇺🇸
Chao Family Comprehensive Cancer Centre, Orange, California, United States
🇺🇸Biogenix Molecular LLC, Miami, Florida, United States
🇺🇸United Theranostics, Glen Burnie, Maryland, United States
External Beam Therapy With Theranostic Radioligand Therapy for Oligometastatic Prostate Cancer (ProstACT TARGET)
- First Posted Date
- 2021-12-07
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
- Target Recruit Count
- 5
- Registration Number
- NCT05146973
- Locations
- 🇦🇺
GenesisCare Murdoch, Perth, Western Australia, Australia
🇦🇺GenesisCare North Shore, St Leonards, New South Wales, Australia
🇦🇺GenesisCare St Andrews, Adelaide, Australia
177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2018-06-04
- Last Posted Date
- 2021-08-24
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 6
- Registration Number
- NCT03545165
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
Neoadjuvant J591 Treatment for Prostate Cancer
- First Posted Date
- 2016-02-29
- Last Posted Date
- 2020-10-05
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 8
- Registration Number
- NCT02693860
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
J591 in Patients With Advanced Prostate Cancer and Unfavorable Circulating Tumor Cell Counts
- First Posted Date
- 2015-09-17
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 10
- Registration Number
- NCT02552394
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors
- Conditions
- Kidney CancerGliomasHead and Neck CancerOvarian CancerEsophageal CancerBreast CancerNon-small Cell Lung CancerColorectal CancerPancreatic Cancer
- Interventions
- First Posted Date
- 2009-08-28
- Last Posted Date
- 2022-02-02
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 20
- Registration Number
- NCT00967577
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic, Castrate-resistant Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2009-06-09
- Last Posted Date
- 2021-05-20
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 15
- Registration Number
- NCT00916123
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
🇺🇸University of North Carolina Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2009-03-11
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 55
- Registration Number
- NCT00859781
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
🇺🇸The University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸USC/Norris Comprehensive cancer center, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.